Investigating the role of immunomodulation for colon cancer prevention: results of an in vivo dose escalation trial of levamisole with immunologic endpoints.

Cancer detection and prevention

Volumn 25, Issue 2, 2001, Pages 183-191

  Holcombe, R F ^a   Milovanovic, T ^a   Stewart, R M ^a   Brodhag, T M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; LEUKOCYTE ANTIGEN; LEVAMISOLE;

ADULT; ARTICLE; BLOOD; CANCER STAGING; CELLULAR IMMUNITY; CLINICAL TRIAL; COLON TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOLOGY; LYMPHOCYTE; MALE; MIDDLE AGED; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIGENS, CD; COLONIC NEOPLASMS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; LEVAMISOLE; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; TH1 CELLS;

EID: 0035222330     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)